Genflow Biosciences Share Discussion Threads

[moneymunch] 18/1/2024 15:47

Still very much under the radar and still cheap as chips, the timing of today's news missed by many and so just the start of some serious UPside, especially as more positive newsflow is very likely in the near term pipeline. Gl :-)

[luckyabbeygale] 18/1/2024 15:18

I guess a lot of us hold different shares here and did not do the right thing in offloading them after seeing that news to buy as many as we can here.

I offloaded some but not enough. I never good at that sort of thing.

[moneymunch] 18/1/2024 14:38

Eric said that he’s expecting a crazy money buy out as soon as the FDA recognise ageing as a disease and he expects it soon, and that’s why he listed in both the UK and US to get the interest of the big pharma above all over companies who work in similar fields. He also said that something similar had happened to him before in another company and the warning signs are there for him once again. Holding tight!

[davealders] 18/1/2024 14:28

I personally don't see the point in looking at the share price. It's a long, long way to go until we reach the heights of before. I'm here for one reason and one reason only.... BUYOUT.
With what's going on here at Genflow, I see a buyout as a massive possibility within the next 2 years and if it takes longer then I'm fully prepared to wait.
Eric will want north of 40p plus per share and with the bottomless bank accounts of the big Pharma companies it will be nothing to them.
Wouldn't surprise me if talks or even references to a buyout has even happen.
Finally looking great again here, news wise.
Good luck all.
Thanks

[moneymunch] 18/1/2024 14:12

We're still awaiting Final reports from the 4 invivo studies to be published, which must be imminent, and should be very well received. Gla :-)

September 2023



The Company is conducting in-vivo evaluations of its centenarian SIRT6 gene therapy in four different NASH mice models in conjunction with four leading partners in the field: The University of Liverpool, UK, The University of Rochester, US, the International Clinical Research Center (FNUSA-ICRC) , Czech Republic and Physiogenex, France.

These studies have been wide reaching and have included the analysation of over 700 mice, with the intention of understanding the efficacy and safety of the Company's drug candidate in animal models with NASH and has generated essential information in preparation for clinical trials in humans. Final reports are expected by the end of 2023.

[kubera369] 18/1/2024 13:51

A rebate lolOr a real re rate It's so overdue and I expect Eric and Genflow to deliver fireworks on the expected news flow coming in any day and throughout this year.The U.S interest should now also build up along with institutional investments.Tiny McapSmall Free Float Unprecedented demand on a hot sector Genflow = the only longevity company holding may patents and the only one listed in the UK and has first mover advantage in Europe Bring on the Re Rate !!!

[northeast14] 18/1/2024 13:42

Fully expect to see a rebate now

[moneymunch] 18/1/2024 13:29

Along way indeed Northeast, but plenty more to come from Eric and Co to get Genflow in full investor focus and market appreciation....Gl :-)

[luckyabbeygale] 18/1/2024 13:11

Those not in may not be able to afford to live forever. As this is one of the companys involved in the latest research that will help abolish old age in around ten years time.

[northeast14] 18/1/2024 12:46

Along way to fill the gap back to 12p!
Hopefully the start of a huge recovery
GLA

[moneymunch] 18/1/2024 12:22

Let's hope Eric has a wad of positive newsflow to deliver in the coming days and weeks...Gla holders...On and UP!!! ;-)

[kubera369] 18/1/2024 12:17

Potential buyout/acquisition target Sitting duck for any pharma predator now and fully funded for years to come SP at under 2p Bargain !!!This year is the year

[moneymunch] 18/1/2024 12:16

Lol...about time too, and much more to come...Genflow is all set for a great year ahead. Gla holders;-)

[lawson27] 18/1/2024 12:15

Nice news, onwards and upwards, GLA

[kubera369] 18/1/2024 12:14

This is mind blowing news Wow!!!On top of more positive news incoming from Genflow Loads going on now with Sirt6 and Anti Ageing This company is just off radar and extremely undervalued Keep buying I say

[manual dexterity] 18/1/2024 12:08

Genflow Biosciences PLC Two Non-Dilutive Research Grant Awards (1848A)
18/01/2024 12:03pm
UK Regulatory (RNS & others)

Genflow Biosciences (LSE:GENF)
Intraday Stock Chart

Thursday 18 January 2024

Click Here for more Genflow Biosciences Charts.
TIDMGENF

RNS Number : 1848A

Genflow Biosciences PLC

18 January 2024

18 January 2024

Genflow Biosciences Plc

("Genflow" or "the Company")

Secures Two Research Grants from Belgium's New Technological Innovation Partnership

The Company (LSE:GNF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process is pleased to announce two significant new research programs in collaboration with Revatis SA and EXO Biologics, backed by substantial non-diluting and non-reimbursable research grants by the Government of Wallonia in Belgium. Funding for the two research programs, as part of the Wallonia Recovery Plan by the Walloon Government in Belgium, will be disbursed annually to the Company, contingent upon Genflow and its collaborators achieving specific, activity-based milestones. Continued receipt of the grants by Genflow is dependent on the parties meeting predefined criteria each applicable year.

Technological Innovation Partnership (ATMP)

The two research programs are a part of a broader innovation partnership that the Walloon Government has launched, dedicated to Advanced Therapy Medicinal Products (ATMPs). The partnership boasts a substantial budget of 81 million euros, a mix of 60% public funding and 40% private contributions from various companies, spread over three years. This initiative is a collaborative effort involving BioWin, the Health Cluster of Wallonia and the Public Service of Wallonia, representing a significant commitment to advancing medical research and development in the region.

Sarcopenia Research Program with Revatis SA

Genflow, together with Revatis SA, has launched a 3-year sarcopenia research program, generously funded by a grant totalling 1.34 million euros. Sarcopenia, the progressive loss of muscle mass and function associated with ageing, poses a significant health risk and affects the quality of life for millions of elderly people worldwide. This collaborative effort aims to expand and diversify Genflow's research pipeline, addressing this growing concern as the global population ages. The partnership will leverage both companies' expertise to develop innovative solutions and contribute valuable insights into the mechanisms of age-related muscle deterioration.

mRNA Delivery Research with EXO Biologics

Genflow and EXO Biologics have initiated a 3-year scientific program, supported by a grant of 1.55 million euros. The project focuses on the development of a novel mRNA delivery system using exosomes to encapsulate and transport Genflow's proprietary centenarian SIRT6 gene. This cutting-edge approach aims to harness the natural advantages of exosomes, such as enhanced stability, improved cellular uptake, reduced immunogenicity, minimal toxicity, natural cargo sorting and reduced off-target effects, among others. This endeavour not only demonstrates Genflow's momentum in leading-edge research, but also holds the potential to revolutionize therapeutic interventions for Werner Syndrome, an accelerated ageing condition and holds great promised for a range of other age-related conditions.

Dr. Eric Leire, CEO of Genflow commented: "We are excited to embark on this exciting new research, which aligns with our quest to understand and alleviate the impacts of ageing. Launching both of these programs represents a strategic move to enhance our research capabilities, while contributing to the understanding of age-related conditions. Both of these strategic initiatives will strengthen Genflow's position at the forefront of ageing-related research, and its mission to improve the health and well-being of older adults."

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

For further information please contact:


Genflow Biosciences Plc
Dr Eric Leire
Chief Executive Officer [phone]
--------------------
Clear Capital Markets
--------------------
Joint Corporate Broker
Bob Roberts [phone]
--------------------
Capital Plus Partners Ltd
--------------------
Joint Corporate Brokers
Dominic Berger [phone]
Keith Swann [phone]
Jon Critchley [phone]
--------------------
Harbor Access
--------------------
Investor Relations
Jonathan Paterson [phone]

[luckyabbeygale] 18/1/2024 11:50

Thank you for correcting me. I was thinking very short term. I have doubled my holding today. While yesterday I had reduced it to buy elsewhere.

[kubera369] 18/1/2024 11:45

Why 100% It was over 5.45p just on the U S Markets listing and this was well over post IPOThe share price is totally out of synchAnd with the low number of shares in issue and the newsflow about to pour on this year I am expecting 10p plus in the not so distant Good luck

[luckyabbeygale] 18/1/2024 11:35

If this is confirmed then expect a 100 rise.

[moneymunch] 18/1/2024 11:12

Game on Northeast, we just need Eric to update the market!!! Gl :-)

[northeast14] 18/1/2024 10:07

€10m grant issued for gene therapy programmeToday 10:05
Taken from LinkedIn, this notes that Genflow are involved in a programme which has just received €10m non dilutive grant funding, for a gene therapy programme from the Belgian government via Wallonia:

GT4Health, an ambitious project focussed on gene therapy and led by the 5 universities of the FWB, was selected as part of the Win4Excellence program of Wallonia!

🧬 Thanks to funding of more than 10 million euros, researchers wish to develop disruptive strategic research in gene therapy, for a holistic strengthening of Wallonia internationally and the sustainability of its value chain.

This research, coordinated by Géraldine Piel, is also a beautiful illustration of the collaborations between the academic world, accredited research centres (CER Group) and industrialists, since several companies are associated with the project: UCB, GenFlow Biosciences, Exothera and QUALIblood s.a.

🤝 For the assembly of this major project, the researchers were also able to count on the support and valuable collaboration of the KTOs of the LiEU Network.

At UMONS, the services of Cell Biology | Lionel Tafforeau & Systems, Estimation, Command and Optimisation (SECO) | Laurent Dewasme and Alain Vande Wouwer are involved. Two doctoral theses will be funded: a first in the SECO service, which will aim at the development of digital twins of AAV (adeno associated virus) production processes in order to optimise their culture conditions, and a second in co-supervision with ULB, which will focus on the development of innovative solutions to optimise genome editing in human haematopoietic stem cells (HSC), intended for gene therapy of primary immunodeficiencies

[moneymunch] 17/1/2024 20:27

GenFlow Biosciences

1,411 followers

17m

With the New Year in full swing, it's easy to want to cheat on any goals you may have set for prolonging your #healthspan. Check out what this article by a Harvard nutrition expert about a few simple ways you can eat for longevity 🧬 “Longevity, of course, is influenced by many factors,” says Dr. Frank B. Hu, a professor of nutrition and epidemiology at the Harvard T.H. Chan School of Public Health.“But diet is one of the most important factors that can impact chronic disease risk, mortality and longevity.”

Read more here: #GenFlowBiosciences #ageing #GENF

[northeast14] 17/1/2024 19:35

Bring it Home Eric!

[moneymunch] 17/1/2024 18:47

Hot off the press, €8.1m awarded to PDC , so hopefully Genflow's next on the list.

[moneymunch] 17/1/2024 18:38

Eric confirmed in his August/September interview that Genflow are in negotiation for two non-dilutive research grants which would provide funds for 80% of their R & D for an additional 3 years, fully cashed well into 2026, and so confrmation news in the pipeline along with an update on their Werner Syndrome accelerated clinical plans highly likely. Gl :-)